TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

175 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Heart / cardiovascular diseaseCOPD (chronic lung disease)

    Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF

    Testing a remote mindful program to increase daily steps in people with COPD and heart failure

    📍 VA Boston · Boston, MA · +1 more US site · Get directions →

    The goal of this fully-remote randomized controlled trial is to test the efficacy of Mindful Steps in facilitating physical activity compared to usual standard of care among 136 patients with COPD and/or HF. The main question it aims to answer is can this intervention promote physical activity as measured by daily step counts in sedentary patients with COPD and/or HF.

    ✓ Study care freeAges 40+Learn more →
  • Heart / cardiovascular diseaseCOPD (chronic lung disease)

    Passive Heat Therapy for People With COPD

    Testing whether a 45-minute hot-water footbath improves blood flow in people with COPD

    📍 University of British Columbia · Kelowna, British Columbia · Get directions →

    People with Chronic Obstructive Pulmonary Disease (COPD) often develop high blood pressure and heart disease due to their sedentary lifestyle and difficulty exercising. The investigators will test if heating can mimic the health benefits of exercise by monitoring the increase in leg blood-flow using ultrasound during a 45-minute hot-water footbath.

    ✓ Study care freeAges 40+Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +1 more US site · Get directions →

    This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Fatty liver disease (NASH/MASH)

    NAFLD Clinical Care Pathway

    Testing a care plan for people with non-alcoholic fatty liver disease

    📍 Michael E. DeBakey VA Medical Center, Houston, TX · Houston, TX · Get directions →

    Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD.

    ✓ Study care freeAges 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

    Testing a new medicine for liver disease in adults with extra body fat

    📍 Altasciences Clinical Company, Inc · Montreal, Quebec · Get directions →

    The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine.

    ✓ Study care freePhase 1Ages 18–69Learn more →
  • Heart / cardiovascular diseaseDepression

    AI Platform for Fatigue and Depression Detection

    Testing how well an AI tool can spot fatigue and depression in heart patients

    📍 Indiana University · Indianapolis, IN · +1 more US site · Get directions →

    This observational study evaluates the accuracy of the Okaya AI platform in detecting fatigue and depression in cardiology patients, comparing its assessments to PHQ-9 and Fatigue Assessment Scale scores.

    ✓ Study care freeAges 18–99Learn more →
  • Fatty liver disease (NASH/MASH)

    A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

    Testing how efimosfermin alfa compares with placebo for MASH with scarred liver tissue

    💵 May compensate

    📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

    The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    The Weight of Cardiovascular Disease

    Testing how a heart and metabolism clinic affects weight loss in obese adults with heart disease

    📍 Mayo Clinic in Rochester · Rochester, MN · Get directions →

    The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

    ✓ Study care freeAges 18+Learn more →
  • Heart / cardiovascular diseaseKidney disease

    The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease

    Studying how kidney transplant affects tiny-heart-vessel blood flow in people with advanced chronic

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    People with chronic kidney disease (CKD) often experience faster aging of the heart and blood vessels, which raises the risk of heart problems beyond traditional factors like high blood pressure or cholesterol. One early sign is reduced blood flow in the tiny vessels that supply the heart, measured by a positron emission tomography (PET) scan using a marker called myocardial flow reserve (MFR).

    ✓ Study care freeAges 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Adapting and Testing a Novel Digital Health Tool (PREVENT) to Improve Health Behavior Counseling and Cardiovascular Health in Rural Primary Care Clinics

    Testing a digital health tool to improve weight and heart care talks in rural clinics

    📍 Washington University in St. Louis · St Louis, MO · Get directions →

    The focus on this application is low-income, rural patients, since cardiovascular disease (CVD) prevalence is 40% higher among rural than urban residents. Health behavior counseling and follow-up care are required for patients with an elevated body mass index who have increased risk for CVD.

    ✓ Study care freeAges 18–64Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure

    A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

    Testing a new digital tool doctors can use to prescribe exercise

    📍 UConn Health · Farmington, CT · +2 more US sites · Get directions →

    The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA.

    ✓ Study care freeAges 18–64Learn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

    Testing QX1206 in people with type 2 diabetes and fatty liver

    📍 Centricity Research Toronto LMC. · Toronto, · Get directions →

    This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose.

    ✓ Study care freePhase 1Ages 18–64Learn more →
  • Fatty liver disease (NASH/MASH)

    Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

    Testing a non-invasive ultrasound way to measure liver fat percentage

    📍 University of Washington · Seattle, WA · Get directions →

    The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD).

    ✓ Study care freeAges 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Androgens and NAFLD Longitudinal Cohort Study

    Studying how male-type sex hormones may affect NAFLD in young women over time

    📍 University of California San Francisco · San Francisco, CA · +1 more US site · Get directions →

    The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring.

    ✓ Study care freeAges 18–42WomenLearn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

    The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Heart / cardiovascular diseaseDepressionAnxiety

    Improving Care and Mental Well-Being for Adults With Heart Failure

    Testing ways to improve mental well-being for adults with heart failure

    📍 Seaway Valley Community Health Centre (Cardiac Rehab Program) · Cornwall, Ontario · Get directions →

    Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives.

    ✓ Study care freeAges 40+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time

    Testing home tools and wearable devices to reduce health harms from evening screen time in people

    📍 Arizona State University · Tempe, AZ · Get directions →

    The purpose of this study is to determine the feasibility, acceptability, efficacy, and participant adherence in using home-based technologies and wearable devices and simple, practical strategies to reduce the negative impact that evening screen time may have on your health.

    ✓ Study care freeAges 26+Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

    Testing how drinking ketone drinks affects heart function in people with type 2 diabetes and heart

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

    Testing whether daily soy milk affects liver disease in children with fatty liver

    📍 Cincinnati Children's Hospital Medical Center · Cincinnati, OH · Get directions →

    A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities.

    ✓ Study care freePhase 2Ages 5–12Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    New Heart Imaging Techniques to Evaluate Possible Heart Disease

    Testing new heart imaging to check for possible heart disease

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: \- Imaging tests, such as magnetic resonance imaging (MRI), can provide information about heart and blood vessels. The tests let doctors can see the amount of blood vessel narrowing and vessel wall thickness.

    ✓ Study care freeAges 18–100Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

    Testing an endoscopic stomach procedure for people with obesity and MASH

    📍 Brigham and Women's Hospital · Boston, MA · +1 more US site · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease.

    ✓ Study care freeAges 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

    Testing a drug to treat fat buildup liver disease in people with stage 2 or 3 fibrosis

    📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Heart / cardiovascular diseaseKidney diseaseCOPD (chronic lung disease)

    Home Hospital for Suddenly Ill Adults

    Testing home-based care for suddenly ill adults with heart, lung, or kidney conditions

    📍 Brigham and Women's Hospital · Boston, MA · +1 more US site · Get directions →

    The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improved patient experience.

    ✓ Study care freeAges 18+Learn more →
  • Heart / cardiovascular disease

    Cereset Research Exploratory Study

    Testing Cereset Research to improve the body’s stress and sleep functions

    📍 Wake Forest University Health Scienc\ess · Winston-Salem, NC · Get directions →

    The purpose of this study is to evaluate the use of Cereset Research to improve autonomic function in participants with symptoms of stress, anxiety, or insomnia.

    ✓ Study care freeAges 11+Learn more →
  • Fatty liver disease (NASH/MASH)

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.

    ✓ Study care freePhase 2Ages 18–100Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health - Chandler · Chandler, AZ · +30 more US sites · Get directions →

    Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse

    ✓ Study care freePhase 2Ages 30+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

    Testing whether two doses of pegozafermin are safe and work for liver scarring in adults with MASH

    📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

    Studying how a fat-tissue immune cell controls fat breakdown in obesity

    📍 University of Missouri School of Medicine · Columbia, MO · Get directions →

    The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.

    ✓ Study care freeAges 18–70Learn more →
  • Heart / cardiovascular disease

    Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)

    Testing whether a potato starch fiber supplement changes gut bacteria and short-chain fats in heart

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut microbiome. The study team also wants to understand if adding potato starch to participant's diet helps these bacteria make more short chain fatty acids, a byproduct the team thinks may benefit participant's health.

    ✓ Study care freeAges 18+Learn more →
  • Heart / cardiovascular disease

    Improving Coronary Vascular Health in Women

    Testing whether blood flow in heart arteries can be improved in women with HIV

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.

    ✓ Study care freePhase 2Ages 45–75WomenLearn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Human Models of Selective Insulin Resistance: Alpelisib, Part I

    Testing how insulin works in healthy people versus people at risk for type 2 diabetes

    💵 May compensate

    📍 Columbia University Irving Medical Center · New York, NY · Get directions →

    The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin.

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Fatty liver disease (NASH/MASH)

    Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

    Testing how SGLT2 inhibitors work for fatty liver disease in obese teens

    💵 May compensate

    📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

    ✓ Study care freePhase 2Ages 16–20Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Fibrosis Lessens After Metabolic Surgery

    Testing whether metabolic surgery can reduce liver scarring in obesity

    💵 May compensate

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

    Testing a drug taken with empagliflozin in adults with type 2 diabetes and heart disease

    📍 Pinnacle Research Group, LLC · Anniston, AL · +39 more US sites · Get directions →

    This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

    Testing a machine method and staged kidney transplant during heart and kidney transplants

    📍 Cedars-Sinai Medical Center · Los Angeles, CA · Get directions →

    The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.

    ✓ Study care freeAges 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility

    Survey to check eligibility for obesity and heart-related clinical trials

    📍 Brooklyn Clinical Research · Brooklyn, NY · Get directions →

    SWIFT-CORE-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, comorbidities, and current symptoms.

    ✓ Study care freeAges 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

    Testing whether pegozafermin is safe and works for MASH-related liver cirrhosis

    💵 May compensate

    📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Heart / cardiovascular diseaseHigh blood pressureKidney disease

    SPYRAL GEMINI Pilot Study

    Testing whether a device that treats nerves in multiple organs is safe and lowers blood pressure in

    📍 Stanford Hospital and Clinics · Stanford, CA · +11 more US sites · Get directions →

    The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.

    ✓ Study care freeAges 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    Testing efimosfermin in people with MASH-related compensated cirrhosis

    💵 May compensate

    📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    NASH AMPK Exercise Dosing (AMPED) Trial

    Testing how much exercise may help people with nonalcoholic fatty liver disease

    📍 Penn State Hershey Medical Center · Hershey, PA · Get directions →

    There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD.

    ✓ Study care freeAges 18–69Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Feasibility of The Health Integrated Nutrition and Kidney Wellness Program

    Testing whether a nutrition and kidney health program is workable for adults with kidney disease

    📍 UPMC Kidney Clinic - Wexford · Pittsburgh, PA · +4 more US sites · Get directions →

    Purpose of the Study: This clinical trial will test whether a nutrition and kidney health program can work well for adults with kidney disease. The program was created with help from patients and community partners.

    ✓ Study care freeAges 18+Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

    Testing how well endoscopic ultrasound stiffness imaging finds liver scarring in people with fatty

    📍 Brigham and Women's Hospital · Boston, MA · +1 more US site · Get directions →

    The goal of this observation study is to assess whether endoscopic ultrasound shear wave elastography (EUS-SWE) may be a useful tool for liver fibrosis screening in patients with elevated body mass index and non alcoholic fatty liver disease as compared to other non-invasive screening modalities, which have traditionally had less accurate results in this population. The main questions it aims to answer are: * Determine accuracy of EUS-SWE for liver fibrosis screening compared to other non-invasive scoring systems, such as the FIB-4 score and Fibroscan in patients with elevated body mass index * Establish optimal stiffness (kPa) cutoffs for liver fibrosis grading for EUS-SWE for this patient population in reference to the gold standard liver biopsy, as no standard cutoffs currently exist.

    ✓ Study care freeAges 18+Learn more →
  • Heart / cardiovascular disease

    The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health

    Testing whether drinking Chardonnay grape marc affects gut and heart health

    📍 University of California, Davis · Davis, CA · Get directions →

    Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples.

    ✓ Study care freeAges 45–70WomenLearn more →
  • Heart / cardiovascular diseaseHigh blood pressureHigh cholesterol

    Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

    Testing a pharmacy-led plan to help people take medicines after hospital discharge

    📍 University of Tennessee Medical Center · Knoxville, TN · +1 more US site · Get directions →

    Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients.

    ✓ Study care freeAges 18+Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure

    Inspire HER: Inspiring the Heart and Emotions for Radical Health

    Testing a heart-health lifestyle program for Black women with poor health

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources).

    ✓ Study care freeAges 30–79WomenLearn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

    Testing whether semaglutide changes heart risk markers in teens with severe obesity

    📍 University of Kentucky · Lexington, KY · Get directions →

    The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment?

    ✓ Study care freeAges 12–17Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Evaluation of a Novel Technology to Support Tailored Health Behavior Counseling in Rural Primary Care Clinics

    Testing a digital tool to improve health counseling for obesity and heart health in rural clinics

    📍 Washington University in St. Louis · St Louis, MO · Get directions →

    This project will conduct a pilot hybrid study that examines the implementation (Aims 1 \& 2) and preliminary effectiveness (Aim 3) of PREVENT, a digital health intervention, among patients with overweight/obesity (N=100) using a clinic-randomized design. The central hypothesis of the study is that PREVENT will be feasible and show improvements in health behavior counseling and the patient experience that will improve patients' motivation to change, and their CVH health behaviors and outcomes.

    ✓ Study care freeAges 18–64Learn more →
  • Fatty liver disease (NASH/MASH)

    Rezdiffra Pregnancy and Lactation Registry

    Tracking pregnancy and baby outcomes after exposure to Rezdiffra in women with NASH

    📍 Madrigal Pharmaceuticals · West Conshohocken, PA · Get directions →

    To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.

    ✓ Study care freeWomenLearn more →
  • Heart / cardiovascular diseaseLupus (SLE)

    The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Testing whether anifrolumab improves blood vessel risk markers in lupus

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Prevention of Progression of Prediabetes, Obesity and CV Risk

    Testing ways to stop prediabetes and obesity from getting worse

    💵 May compensate

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children

    Testing whether whole or nonfat milk changes body composition in children

    📍 New Balance Foundation Obesity Prevention Center · Boston, MA · Get directions →

    This study will evaluate the effects of whole vs. nonfat milk consumption on body composition, cardiometabolic disease risk factors, and dietary quality.

    ✓ Study care freeAges 9–12Learn more →
  • Fatty liver disease (NASH/MASH)

    Evaluating the Pharmacokinetics and Safety of Miricorilant

    Testing how a drug works in the body and its safety in adults with MASH

    💵 May compensate

    📍 Site# 433 · San Antonio, TX · Get directions →

    A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

    Testing a medicine at two doses for safety and effects on fats in people with high triglycerides and

    💵 May compensate

    📍 OrsoBio Research Site · Guadalajara, Jalisco · Get directions →

    This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • Fatty liver disease (NASH/MASH)

    Bicalutamide Therapy in Young Women With NAFLD and PCOS

    Testing bicalutamide in young women with fatty liver inflammation (NASH) and PCOS

    📍 University of California San Francisco · San Francisco, CA · Get directions →

    Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years. Women are at disproportionate risk for NASH, with approximately 15 million U.S.

    ✓ Study care freePhase 1Ages 18–42WomenLearn more →
  • Type 2 diabetesHeart / cardiovascular diseaseKidney disease

    Food and Fitness With Medicine (FFWM)

    Testing a food and fitness program to reduce stopping type 2 diabetes medication in postmenopausal

    📍 Ohio State Healthy Community Center · Columbus, OH · +3 more US sites · Get directions →

    Food and Fitness with Medicine (FFWM) is a 24-week randomized controlled trial (RCT) enrolling 200 post-menopausal women (PMW) with stage 2 cardio-kidney metabolic (CKM) syndrome and type-2 diabetes (T2D) within 6 weeks of initiating glucagon-like peptide-1 receptor agonist (GLP-1RAs) to: 1. Examine discontinuation rates of GLP-1RAs (primary outcome); 2.

    ✓ Study care freeAges 18+WomenLearn more →
  • Fatty liver disease (NASH/MASH)

    Thermoacoustic Method for Estimating Liver Fat Fraction

    Testing a new ultrasound method to measure liver fat compared with MRI

    📍 ENDRA Life Sciences · Ann Arbor, MI · Get directions →

    The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements. Participants will have a scan with our device, then they will go have an abdominal MRI completed.

    ✓ Study care freeAges 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity

    📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    ✓ Study care freePhase 3Ages 45–99Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people

    💵 May compensate

    📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).

    ✓ Study care freePhase 3Ages 18–99Learn more →
  • Showing the first 60 of 175. Add filters or a location to narrow down.